Quinic Acid-Modified Nanoparticles for E-Selectin Targeted Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanoparticle-based chemotherapy for cancer faces challenges due to low accumulation in tumors and lack of clinical evidence supporting its benefits, primarily because of the diverse nature of cancer and variable efficiency of the enhanced permeability and retention (EPR) effect, necessitating additional means to enhance delivery efficiency.
Innovation Solution
Development of quinic acid-modified nanoparticles (QANPs) that target E-selectin-positive cells or tissues, using a combination of nanoparticles coated with a polyphenol compound and modified with a quinic acid derivative, allowing for enhanced interaction with activated endothelial cells and increased transendothelial transport.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional nanoparticle delivery methods are used, then the nanoparticle structure is simple and easy to manufacture, but the accumulation in tumors is low due to variable EPR effect efficiency
Solution Approach 1:
The nanoparticle delivery system is segmented into multiple functional components: a core nanoparticle structure, a polyphenol coating layer, and quinic acid ligands. This segmentation allows each component to perform its specific function - the core provides structural integrity, the polyphenol coating enables endothelial cell interaction, and the quinic acid ligands provide selective targeting - thereby improving tumor accumulation without overwhelming manufacturing complexity
Solution Approach 2:
The invention employs composite materials by combining the nanoparticle core with polyphenol compounds and quinic acid derivatives. This composite structure integrates the advantages of each material: the nanoparticle provides drug loading capacity, the polyphenol coating enhances stability and cellular interaction, and the quinic acid moiety provides selective binding to E-selectin, collectively improving tumor delivery efficiency
2Productivity
If passive EPR effect-based delivery is used, then the delivery mechanism is simple, but the delivery efficiency is low due to diverse cancer characteristics
Solution Approach 1:
The nanoparticle surface is preliminarily functionalized with quinic acid ligands before administration. This preliminary action enables the nanoparticles to proactively bind to E-selectin on activated endothelial cells, facilitating active transcytosis across the endothelial barrier and into the tumor tissue, thereby significantly improving delivery efficiency beyond passive EPR accumulation
Solution Approach 2:
The quinic acid ligand acts as an intermediary that mediates the interaction between the nanoparticle and the E-selectin receptor on endothelial cells. This intermediary mechanism enables specific recognition and binding, facilitating active transport across the endothelial barrier and improving delivery efficiency without requiring complex multi-component systems
3Reliability
If nanoparticle coating with polyphenol and quinic acid is implemented, then the targeting specificity to E-selectin-positive cells is improved, but the manufacturing process becomes more complex
Solution Approach 1:
The invention utilizes parameter changes in the chemical modification process, specifically controlling the conjugation conditions of quinic acid to the polyphenol-coated nanoparticle surface. By optimizing parameters such as pH, temperature, and reaction time, the process achieves high targeting specificity through controlled ligand density and orientation, while maintaining manufacturing feasibility through a single-step conjugation approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
QANPs demonstrate improved accumulation in tumors and enhanced anti-cancer efficacy compared to traditional nanoparticle delivery methods, as they actively interact with E-selectin-positive endothelial cells, increasing extravasation and tumor drug delivery efficiency.
Implementation Method 1
quinic acid-modified nanoparticles (QANPs) that target E-selectin-positive cells or tissues
Implementation Method 2
enhanced interaction with activated endothelial cells and increased transendothelial transport
Data Source
AI summary
The present invention generally relates to targeted nanoparticle delivery to E-selectin- or P-selectin-positive cells or tissues. In particular, this invention discloses a method for preparing quinic acid-modified nanoparticles for targeted drug delivery to cancerous cells or tissues via E-selectin- or P-selectin-mediated transcytosis. The invention described herein also pertains to pharmaceutical compositions and methods for treating cancers.